Hypomethylating agents for the treatment of myelodysplastic syndromes and acute myeloid leukemia: Past discoveries and future directions
Nicholas J. Short, Hagop M. Kantarjian
Abstract
Azacitidine and decitabine are hypomethylating agents that have dose-dependent epigenetic and cytotoxic effects and are widely used in the treatment of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). In this review, we discuss the path to regulatory approval of azacitidine and decitabine, highlighting the substantial efforts that have been made to optimize the dosing schedule and administration of these drugs, including the development of new, oral formulations of both agents. We also review novel combination strategies that are being investigated in ongoing clinical trials for patients with MDS and AML, as well as efforts to expand the current indications of these agents.
Topics & Concepts
DecitabineAzacitidineMyelodysplastic syndromesMedicineMyeloid leukemiaHypomethylating agentClinical trialLeukemiaOncologyMyeloidInternal medicineDNA methylationBone marrowBiologyGene expressionGeneBiochemistryAcute Myeloid Leukemia ResearchHistone Deacetylase Inhibitors ResearchPneumocystis jirovecii pneumonia detection and treatment